Indication: For unresectable locally advanced or metastatic gastric cancer.

Indication: OPDIVO QVANTIG is a combination of nivolumab (a PD-1 blocking antibody) and hyaluronidase indicated for the treatment of multiple cancers, including renal cell carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, used as monotherapy or in combination with chemotherapy or targeted agents in first-line, neoadjuvant, adjuvant, and previously treated settings, with certain indications requiring specific biomarker status, prior therapies, or being approved under accelerated approval based on response rate and duration.

Indication: Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer 1. 1 Breast Cancer 1. 2 Gastric, Esophageal, or Gastroesophageal Junction Cancer 1. 3 Pancreatic Cancer 1. 4 Capecitabine tablet is indicated for the: Capecitabine tablet is indicated for the: Capecitabine tablet is indicated for the: Capecitabine tablet is indicated for the adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Indication: OPDIVO QVANTIG is a combination of nivolumab and hyaluronidase indicated for the treatment of multiple cancers, including renal cell carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, used as monotherapy or in combination with chemotherapy or targeted agents in various first-line, adjuvant, neoadjuvant, and previously treated settings, with some indications subject to specific biomarker status, prior therapies, or accelerated approval based on response rates.